Asthma is a long-term condition with rapid onset worsening of symptoms which can be unpredictable and fatal. Prediction models require high sensitivity to minimise mortality risk, and high specificity to avoid unnecessary prescribing of preventative medications that come with a risk of adverse events. We aim to create a risk score to predict asthma attacks in primary care using a statistical learning approach trained on routinely collected Electronic Health Record (EHR) data. We will investigate the potential added value across various metrics (including sensitivity and specificity) by extending the statistical learning model, incorporating information extracted from linked secondary care records in addition to the primary care EHR data.
INTRODUCTION
Asthma is a long-term lung disease characterised by inflammation of the airways, which may manifest as episodic wheezing, chest tightness, coughing and shortness of breath. An asthma attack is the sudden worsening of symptoms, which may prove fatal 1 . In 2017, asthma was estimated to affect 235 million people worldwide 2 . In 2015 alone, 1,434 people died from asthma attacks in the United Kingdom (UK) -a rate of 2.21 deaths per 100,000 person-years 3 .
Asthma therapy typically follows a fairly linear path -beginning with a short-acting bronchodilator in those without persistent asthma symptoms, and adding preventative treatments and long-acting bronchodilators in those with more persistent asthma symptoms 4, 5 .
Those with persistent troublesome symptoms and/or considered to be at very high risk may be prescribed biologicals and/or oral steroids 6 . Oral steroids are often considered a last resort, due to their undesirable safety profile including increased risk of diabetes [7] [8] [9] , osteoporosis [10] [11] [12] , and psychotic and affective disorders [12] [13] [14] [15] .
It follows that the determination of those at high risk for asthma attacks is crucial in order to prevent attacks and minimise the risk of side-effects. Furthermore, the 2014 National Review of Asthma Deaths found that 45% of asthma deaths in the study year died without requesting medical help, or before that help could be provided 16 . Increased awareness of the risk could prevent those with asthma from delay in seeking medical care and preventing fatality.
While it might seem intuitive that those with the most severe asthma, i.e. those with continuous symptoms that are not controlled by medication, exhibit greater risk of severe morbidity and mortality, research suggests that daily symptoms may be a suboptimal clinical marker of disease severity 17 . Indeed, some people with asthma are more prone to attacks than others, with past attack history being commonly found to be one of the strongest risk factors for future attacks [18] [19] [20] [21] . Other commonly identified risk factors for asthma attacks include poor asthma control [22] [23] [24] [25] (often a result of poor adherence to preventative therapy [26] [27] [28] [29] ), smoking 22, 25, [30] [31] [32] , history of hospital admission 19, 22 , history of oral steroid use 22 , obesity 25, [32] [33] [34] [35] [36] , socio-economic factors such as access to medicines 37, 38 socioeconomic status 39, 40 , and viral respiratory infections [41] [42] [43] .
Despite the identification of many risk factors, identifying high risk patients has proven a challenging task. Logistic regression, the most commonly used statistical method for event prediction, is known to predict outcomes poorly when class sizes (event and no event) are imbalanced 44 . As such, most prediction models report high specificity (correctly predicting low attack risk to those who did not have attacks) but low sensitivity (correctly predicting high risk in those who did go on to have attacks) 22, 39, [45] [46] [47] [48] [49] [50] , which results in less reliable risk prediction for the most at risk patients.
In a recent study by Finkelstein and Jeong 51 , sensitivity (and specificity) in excess of 75% was achieved for all classifiers (Adaptive Bayesian network, Naïve Bayes classifier, and Support Vector Machine) predicting asthma attacks a week in advance using a sample of just over 7000 records of home tele-monitoring data. They found substantial improvements in model sensitivity using training enrichment methods; pre-processing the training data to improve the performance in the testing data -in this case, modifying the prevalence of the outcome in the training data by stratifying samples to balance the classes. 
RESEARCH AIM
We aim to create a risk score for primary care clinicians to predict asthma attacks in the following 1, 4, 26, and 52 weeks, employing machine learning methodologies such as random forests, naïve Bayes classifiers, and support vector machines, as well as ensemble algorithms. Secondly, we aim to explore the potential added value of possible future routine data linkages, such as secondary care records, to investigate improved ability to predict asthma attacks.
METHODS

Data Sources and Permissions
The derivation dataset used for training, validating, and testing the model will be the Asthma Learning Healthcare System (LHS) dataset, created in order to develop and validate a prototype learning health system for asthma patients in Scotland 52 . The LHS study aimed to increase understanding of variation in asthma outcomes and create benchmarks for clinical practice in order to reduce sub-optimal care, by repurposing patient data to create a continuous loop of knowledge-generation, evidence based clinical practice change, and change assessment. The study dataset contains patient demographics from the patient registry, primary care prescribing records, primary care encounters, Accident and Emergency (A&E) records, hospital inpatient admissions and deaths, linkable by an anonymised identifier. Datasets were extracted between November 2017 and August 2018 for the period January 2000 to December 2017, as shown in Table 1 , along the number of records and unique individuals before data cleaning.
In order to externally verify the prediction model, we will evaluate its performance using an external cohort study dataset, the second Seasonal Influenza Vaccination Effectiveness (SIVE II) cohort study 53, 54 , which used a large national primary care (1.25 million individuals from 230 Scottish general practices) and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness. The dataset contains records from the same sources (primary and secondary care) and modalities (diagnosis and date) as the LHS dataset (extraction and specification dates are shown in Table 2 ), and as such can be harmonised such that variables and value sets are aligned. In Appendix A, we detail the data harmonisation plan, that is, we list the key variables to be used in the following analyses, their format in each dataset (for example, whether age is pre-coded into 5-year bands) and the common denominator format that will be used in the analyses to ensure the highest degree of concordance during the validation stage.
F o r p e e r r e v i e w o n l y are very grateful. A lay summary of the results of this study will be disseminated after publication.
Inclusion Criteria
We will identify our study population as all individuals with asthma identified by clinical diagnoses (Read codes) and relevant prescribing records in primary care. Patients with missing sex or age information will be removed; this and any other patient exclusions from further analysis will be explicitly detailed.
All records from the derivation dataset (LHS) will be left-censored at January 2010, in order to align with the primary care prescribing data, and right-censored at March 2017, in order to align with the mortality, primary care Read code, and inpatient hospital admission records, are presented in Table 1 . Similarly, records from the external dataset (SIVE II) will be leftcensored at January 2003, in order to align with the primary care prescribing data, and rightcensored at August 2016 to align with the A&E records, as shown in Table 2 . There is a high probability that some individuals having been recruited into both studies, and so such individuals will be flagged in the external testing dataset and removed from the study pool. 
Outcome Ascertainment
We will identify asthma attacks, defined by the American Thoracic Society/European Respiratory Society 55 as either a prescription of oral corticosteroids, an asthma-related A&E visit, or an asthma-related hospital admission. Additionally, deaths occurring with asthma as the primary cause will be labelled as asthma attacks. Instances of multiple attack indicators occurring within a 14-day period were coded as a single attack.
Patient characteristics, confounders, and missing data handling
Patient characteristics will be presented at baseline and included as confounders in analyses. For all characteristics derived from Read codes, full code lists will be provided as supplementary materials.
Demographics: Age, sex, rurality, and social deprivation will be extracted from the primary care registry. Social deprivation is measured using quintiles of the Scottish Index of Multiple Deprivation (SIMD), a geographic measure derived using data on income, employment, education, health, access to services, crime and housing 56 . Rurality is defined using the Scottish Government Urban Rural Classification Scale (6-fold scale) 57 . While missing age and/or sex are exclusion criteria for the study sample, missingness for rurality and social deprivation within the registry will be coded as 'missing'.
Practice Location: Practice location will be included in order to account for clustering of patients by region. Location will be coded using the Nomenclature of Territorial Units for Statistics 58 (NUTS 3) codes, linked from the registered practice data zone (2001) available in the patient registry.
Asthma Severity: Patient asthma severity will be categorised using the British Thoracic Society's 2016 5-step treatment classification 59 . Severity will be considered time-dependent and will be determined using prescribing records at any change in regimen.
Smoking Status: Smoking status will be derived from primary care data, and presented as a 3-level variable, namely: current, former, and non-smoker, using the most recent smoking Read code at any day. Those with unknown smoking status will be coded as non-smokers 60, 61 . Smoking status will be considered time-dependent and determined using the most recent Read code records at the start of each study year.
Blood Eosinophil Count:
Blood eosinophil count will be derived from primary care Read codes, and will be dichotomised at >=400 cells per μL. Those with unknown Blood eosinophil count will be coded as negative for raised eosinophil count. Blood eosinophil count will be considered time-dependent and determined using the most recent Read code records at the start of each study year.
Obesity: Obesity will be derived from Body Mass Index (BMI) recordings in primary care data, and will be presented as a binary variable (BMI≥30). Those with unknown BMI will be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y coded as non-obese. Obesity will be considered time-dependent and determined using the most recent Read code records at the start of each study year.
Comorbidity: Comorbidity will be defined by 17 dichotomous (unweighted) variables representing the diagnostic categories of the adapted Charlson Comorbidity Index 62, 63 . Additionally, active diagnoses of rhinitis, eczema, Gastroeosophageal Reflux Disease (GERD), nasal polyps, and anaphylaxis will be recorded; all identified by Blakey et al. as contributing characteristics to increased asthma attack risk 64 . Comorbidities will be considered timedependent and determined using Read code records prior to the start of each study year.
Previous Healthcare Usage:
The number of repeat prescriptions of preventer medication, and the number of primary care asthma encounters (days on which at least one asthma related code was recorded) in the previous year will be derived from primary care prescribing and Read code records, respectively. Both will be considered time-dependent and determined using records from the previous calendar year.
Asthma Control:
The mean Short-Acting Beta-2 Agonist (SABA) dose per day will be estimated retroactively by examining the dates between prescriptions. The most recent peak expiratory flow measurement at any time will be recorded (categorical, based on percentage of previous maximum) or coded as missing if that measurement was more than seven days ago. Adherence to preventer therapy will be approximated using the medication possession ratio, calculated from primary care prescribing records.
History of Asthma Attacks: Asthma attacks will be identified using both primary care prescribing records and secondary care records for outcome ascertainment. Prior asthma attacks will also be used as a predictor, however, and for this purpose will be identified from primary care prescribing records and primary care Read codes only. This is because primary care practitioners will not be able to make use of secondary care records when utilising this risk score with patients. Both the prior number of attacks, and the time since the last attack, will be included as predictors and will be considered time-dependent and accurate at the daily level.
Analysis Plan
A multivariate repeated-event survival analysis will be used to assess the contributing risk factors of time-to-asthma-attack, consisting of static demographic variables and time-varying data such as season and historical asthma records.
The derivation dataset (LHS) will be divided into three partitions: 60% for training, 20% for model comparison (validation), and 20% to assess performance (testing). In our training subset, the first partition, we will train machine learning models (classifiers) with varying hyperparameters, predicting asthma attack occurrence in the following 1, 4, 26, and 52 weeks. We will run 100 iterations for statistical confidence, each time randomly permuting samples prior to determining the three subsets. The classifiers employed will include random forests, naïve Bayes classifiers, and support vector machines, as well as ensemble learning using combinations of these models.
A selection of training enrichment methods will be trialled, in order to assess how to best overcome poor performance as a result of low outcome prevalence. Typically, modelling rare events results in reduced sensitivity (the proportion of those who had attacks that were detected), so those predicted to be low-risk will have a high rate of asthma attacks. As such, this start of this process (the first 20 iterations of training each model) will be repeated five times, using:
1. the raw data, 2. raw data + duplicates of the positive outcome records (a method known as oversampling 65 ), 3. raw data -a selection of the negative outcome records (under-sampling 65 ), 4. raw data + slightly modified duplicates of the positive outcome records -a selection of the negative outcome records (Synthetic minority over-sampling; SMOTE 65, 66 ), 5. raw data, using the outcome classification threshold to maximise the MCC metricidentified using golden-section search optimisation 67 .
By assessing the average performance, by classification method class, in each set of iterations, we will determine which enrichment method is the most appropriate overall for the data, and continue accordingly.
In the validation partition, with all 100 iterations for the selected enrichment methods, we will compare the performance of each trained model, using our primary metric -the Matthew's Correlation Coefficient (MCC) 68 . From here, the performance of each model within an iteration will be ranked. Across iterations, the highest performing model will be selected as follows:
1. Models with a median MCC (across iterations) lower than the 90 th percentile for all models and iterations will be removed; 2. The model with the highest mean MCC (across iterations) is selected; in the event of a tie, the model with the highest worst-performing iteration will be selected.
Model testing will be conducted on the selected model ( Figure 1 ) in the derivation testing partitions. Model calibration will be assessed by comparing observed rate of incidence by predicted risk, for the full population and by exhaustive population subgroups. Performance in the testing datasets will be assessed using the MCC, and the additional metrics of sensitivity, specificity, positive predictive value and negative predictive value, and the F 1 measure 69 , along with information criteria such as the Bayesian Information Criterion (BIC) to obtain a trade-off between model complexity and accuracy. Confusion matrices (also known as contingency tables) will be made available as supplementary materials.
The derivation dataset will be re-used in its entirety to retrain the model based on the final classifier and hyperparameter selection. Model testing will then be conducted in the external dataset, which consists of data unseen in the model derivation, using this trained model. Distributions of predictors between the derivation and external datasets will be assessed (indirectly) to contextualise the generalisability findings. The aforementioned metrics will be reported.
Finally, we will re-train the derivation dataset using the hyperparameter specifications from the best performing model, and incorporating data extracted from secondary care records (such as A&E presentations for asthma attack not captured in primary care records), in order to evaluate the added value of secondary care data linkage for this predictor, determined by the same metrics used for model evaluation. 
Data statement
The derivation and external datasets used in this study are accessible via the eDRIS secure platform under the project numbers 1516-0160 and 1516-0489, respectively.
Conclusions
This project will further advance asthma attack risk prediction modelling and will inform on the future direction of routine data linkage in Scotland, which is likely to have additional benefits for other health systems in the United Kingdom and internationally. 
Appendix B -Machine Learning classifier hyperparameters Naïve Bayes Classifier
Implemented using the r function naivebayes, from the package of the same name 72 . No hyperparameters.
Support Vector Machine
Implemented using the r function svm, from the package e1071 73 which builds upon the LIBSVM package 74 Ensemble: Bagging Bagging methods learn from multiple models which are staged in parallel.
Random Forests
Implemented using the r function randomForest, from the package of the same name 75 .
-NTREE = Number of trees to grow (default 500): 500, 750, 1000 -MTRY = Number of variables randomly sampled as candidates at each split (default square root of the number of predictors; k): floor( , floor( , floor(2* -in 0.5 * ) ) ) which floor represents the rounded-down integer value.
Ensemble: Boosting
Learning from multiple models which are staged sequentially, usually tree-based, constructed from different subsamples of the training dataset. Extreme Gradient Boosting Implemented using the r package xgboost 76 , with 10-fold cross validation, repeated 3 times.
-NROUNDS = maximum number of iterations (default 100): 50,100 -MAXDEPTH = Maximum depth of each tree (default = 6): (1:5)^2 -ETA = step size of each boosting step (default = 0.3): 0.25, 0.5, 1
Ensemble: Stacking
Combining models from different classifiers, with an over-arching supervisor model which determines the best way to use all sources of information for prediction. The base set of weak learners will comprise all aforementioned model and hyperparameter combinations, and the meta-learner (random forest with 500 trees and mtry = floor( ) will use all weak 0.5 * ) learners with a validation set performance in the top 50%. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
ABSTRACT Introduction
Asthma is a long-term condition with rapid onset worsening of symptoms ('attacks') which can be unpredictable and may prove fatal. Models predicting asthma attacks require high sensitivity to minimise mortality risk, and high specificity to avoid unnecessary prescribing of preventative medications that carry an associated risk of adverse events. We aim to create a risk score to predict asthma attacks in primary care using a statistical learning approach trained on routinely collected electronic health record (EHR) data.
Methods and Analysis
We will employ machine learning classifiers (naïve Bayes, support vector machines, and random forests) to create an asthma attack risk prediction model, using the Asthma Learning Health System (ALHS) study patient registry comprising 500,000 individuals from across 75 Scottish general practices, with linked longitudinal primary care prescribing records, primary care Read codes, accident and emergency records, hospital admissions and deaths. Models will be compared on a partition of the dataset reserved for validation, and the final model will be tested in both an unseen partition of the derivation dataset and in an external dataset from the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. Asthma therapy typically follows a fairly linear path -beginning with a short-acting bronchodilator in those without persistent asthma symptoms, and adding preventative treatments and long-acting bronchodilators in those with more persistent asthma symptoms 7, 8 . Those with persistent troublesome symptoms and/or considered to be at very high risk may be prescribed biologicals and/or oral steroids 9 . Oral steroids are often considered a last resort, due to their undesirable safety profile including increased risk of diabetes [10] [11] [12] , osteoporosis [13] [14] [15] , and affective and psychotic disorders [15] [16] [17] [18] .
Ethics and Dissemination
It follows that the determination of those at high risk for asthma attacks is crucial in order to prevent attacks and minimise the risk of unnecessary side-effects. Furthermore, the 2014 National Review of Asthma Deaths found that 45% of asthma deaths in the study year died without requesting medical help, or before help could be provided 5 . Increased awareness of the risk could prevent those with asthma from delay in seeking medical care and preventing fatality.
While it might seem intuitive that those with the most severe daily symptoms exhibit greater risk of severe morbidity and mortality, research suggests that these symptoms may be a suboptimal clinical marker of asthma attack risk 19 . Indeed, some people with asthma are more prone to asthma attacks than others, with past asthma attack history being the strongest risk factor for future asthma attacks [20] [21] [22] [23] . Other commonly identified risk factors for asthma attacks include poor asthma control [24] [25] [26] [27] (often a result of poor adherence to preventative therapy [28] [29] [30] [31] ), smoking 24, 27, [32] [33] [34] , history of hospital admission 21, 24 , history of oral steroid use 24 , obesity 27, [34] [35] [36] [37] [38] , socio-economic factors such as access to medicines 39, 40 socioeconomic status 41, 42 , and viral respiratory infections [43] [44] [45] .
Despite the identification of many risk factors, identifying high risk individuals has proven a challenging task. Logistic regression, the most commonly used statistical method for event prediction, is known to predict outcomes poorly when there is class imbalance (event and no event) 46 , and we expect the problem investigated in this study assessing asthma attacks will be highly imbalanced. For example, a model could predict that a very rare event would never occur, and it would be correct in the vast majority of cases. As such, most prediction models report high specificity (correctly predicting low attack risk to those who did not have attacks), but low sensitivity (correctly predicting high risk in those who did go on to have attacks) 4, 24, 41, [47] [48] [49] [50] [51] , which results in less reliable risk prediction for patients at high risk.
In a recent study by Finkelstein and Jeong 52 , sensitivity (and specificity) in excess of 75% was achieved for all classifiers (Adaptive Bayesian network, Naïve Bayes classifier, and Support Vector Machine) predicting asthma attacks a week in advance using a sample of just over 7000 records of home tele-monitoring data. They found substantial improvements in model sensitivity using training enrichment methods; pre-processing the training data to improve the performance in the testing data -for example, by increasing the prevalence of the rare outcome in the training data to balance the classes.
RESEARCH AIM
We aim to create a personalised risk assessment tool to assist primary care clinicians in predicting asthma attacks over a period of 1, 4, 12, 26, and 52 weeks, employing machine learning methodologies such as naïve Bayes classifiers, random forests, and support vector machines, as well as ensemble algorithms. The model will build on previous research 4, 24, 41, [47] [48] [49] [50] [51] [52] to improve the sensitivity of our event prediction, without unduly compromising the specificity. This is crucial in order to reduce steroid prescribing and diminish the long-term effects of high steroid use over a life time, which have adverse effects [10] [11] [12] [13] [14] [15] [16] [17] [18] , and reduce patient anxiety when risk of an asthma attack is low.
Primary care consultations provide the opportunity for patients and clinicians to assess changes to asthma attack risk, which can be used to promote patients to seek emergency care if there is a significant deterioration in their symptoms, and to promote risk-reducing lifestyle choices.
METHODS
Data Sources and Permissions
The derivation dataset used for training, validating, and testing the model will be the Asthma Learning Healthcare System (ALHS) dataset, created in order to develop and validate a prototype learning health system for asthma patients in Scotland 53 . The ALHS study aims to increase understanding of variation in asthma outcomes and create benchmarks for clinical practice in order to reduce sub-optimal care, by repurposing patient data to create a continuous loop of knowledge-generation, evidence-based clinical practice change, and change assessment. The study dataset contains patient demographics from the patient registry, primary care prescribing records, primary care encounters, Accident and Emergency (A&E) records, hospital inpatient admissions and deaths, linkable by an anonymised unique identifier. Datasets were extracted between November 2017 and August 2018 for the period January 2000 to December 2017, as shown in Table 1 , along with the number of records and unique individuals before data cleaning.
In order to verify that the prediction model performance is not limited to the development dataset and that it generalizes well in new, unseen data presented to the classifier in the training process, we will evaluate its performance using an external cohort study dataset, the second Seasonal Influenza Vaccination Effectiveness (SIVE II) cohort study 54, 55 , which used a large national primary care (1.25 million individuals from 230 Scottish general practices) and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness. The SIVE II dataset contains records from the same sources (primary and secondary care) and modalities (diagnosis and date) as the ALHS dataset (extraction and specification dates are shown in Table 2 ), and as such can be harmonised such that variables and value sets are aligned. In Appendix A, we detail the data harmonisation plan, that is, we list the key variables to be used in the following analyses, their format in each dataset (for example, whether age is pre-coded into 5-year bands) and the common denominator format that will be used in the analyses to ensure the highest degree of concordance during the validation stage. 
Patient and Public Involvement
This analysis plan was constructed with the assistance of the Asthma UK Centre for Applied Research (AUKCAR) Patient and Public Involvement (PPI) group. The particular importance of avoiding a substantial decrease in specificity in order to gain higher sensitivity was a result of discussions within this group about the burden of side-effects from preventative treatment.
Inclusion Criteria
We will identify our study population as all adults (aged 18 and over) with asthma identified by clinical diagnoses (Read codes), without a chronic obstructive pulmonary disease (COPD) diagnosis, and with relevant prescribing records in primary care. Patients with missing sex or age information will be removed; this and any other patient exclusions from further analysis will be explicitly detailed.
All records from the derivation dataset (ALHS) will be left-censored at January 2009, in order to align with the primary care prescribing data, and right-censored at March 2017, in order to align with the mortality, primary care, and inpatient hospital admission records, are presented in Table 1 . Similarly, records from the external dataset (SIVE II) will be left-censored at January 2003, in order to align with the primary care prescribing data, and right-censored at August 2016 to align with the A&E records, as shown in Table 2 . There is a high probability that some individuals will have been recruited into both studies, and therefore those individuals will be flagged in the external testing dataset and removed from the study pool. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Outcome Ascertainment
We will identify asthma attacks, defined by the American Thoracic Society/European Respiratory Society 56 as either a prescription of oral corticosteroids, an asthma-related A&E visit, or an asthma-related hospital admission. Additionally, deaths occurring with asthma as the primary cause will be labelled as asthma attacks. Instances of multiple attack indicators occurring within a 14-day period were coded as a single attack.
Patient Characteristics, Confounders, and Missing Data
Patient characteristics at baseline will be reported, and included as time-varying confounders in analyses. For all characteristics derived from Read codes, full code lists will be provided as supplementary materials.
Demographics: Age, sex, rurality, and social deprivation will be extracted from the primary care registry. Social deprivation is measured using quintiles of the Scottish Index of Multiple Deprivation (SIMD), a geographic measure derived using data on income, employment, education, health, access to services, crime and housing 57 . Rurality is defined using the Scottish Government Urban Rural Classification Scale (6-fold scale) 58 . While missing age and/or sex are exclusion criteria for the study sample, missingness for rurality and social deprivation will be coded as 'missing'.
Practice Location: Practice location will be included in order to account for clustering of patients by region. Location will be coded using the Nomenclature of Territorial Units for Statistics 59 (NUTS 3) codes, linked from the registered practice data zone (2001).
Asthma Severity: Asthma severity will be categorised using the British Thoracic Society's 2016 5-step treatment classification 60 . Severity will be considered time-dependent and will be determined using prescribing records at any change in regimen.
Smoking Status: Smoking status will be derived from primary care data, and presented as a 3-level variable, namely: current, former, and non-smoker, using the most recent smoking Read 
code at any day. Smoking status will be considered time-dependent and determined using the most recent Read code records, and those with unknown smoking status will be coded as nonsmokers 61, 62 .
Blood Eosinophil Count:
Blood eosinophil count will be derived from primary care Read codes, and will be dichotomised at ≥400 cells per μL. Those with non-recorded blood eosinophil count will be coded as missing. Blood eosinophil count will be considered timedependent and determined using the most recent Read code record.
Obesity: Obesity will be derived from Body Mass Index (BMI) or height and weight records in primary care data, and will be presented as a binary variable (BMI≥30). Those with unknown BMI will be coded as non-obese. Obesity will be considered time-dependent and determined using the most recent Read code record.
Comorbidity: Comorbidity will be defined by 17 dichotomous (unweighted) variables representing the diagnostic categories of the adapted Charlson Comorbidity Index 63, 64 . Additionally, active diagnoses of rhinitis, eczema, gastroesophageal reflux disease (GERD), nasal polyps, and anaphylaxis will be recorded; all identified by Blakey et al. as contributing characteristics to increased asthma attack risk 65 . Comorbidities will be considered timedependent and determined using all prior Read code records.
Previous Healthcare Usage:
Asthma Control:
The mean Short-Acting Beta-2 Agonist (SABA) dose per day will be estimated retroactively by examining the dates between prescriptions. The most recent peak expiratory flow measurement at any time will be recorded (categorical, based on percentage of previous maximum) or coded as missing if that measurement was more than seven days ago. Adherence to preventer therapy will be approximated using the medication possession ratio 66 , calculated from primary care prescribing records.
History of Asthma Attacks:
Prior asthma attacks will be identified solely using primary care prescribing records and Read codes. This is because primary care practitioners will not be able to make use of secondary care records when utilising this risk score with patients. Both the prior number of attacks, and the time since the last attack, will be included as predictors and will be considered time-dependent and accurate at the weekly level.
Analysis Plan
The derivation dataset (ALHS) will be divided into three partitions: 60% for training, 20% for model comparison (validation), and 20% to assess performance (testing). In our training subset, the first partition, we will train machine learning models (classifiers) with varying hyperparameters, predicting asthma attack occurrence in the following 1, 4, 26, and 52 weeks. We will run 100 iterations for statistical confidence, each time randomly permuting samples prior to determining the three subsets. The no free lunch theorem in machine learning suggests there is no classifier (or more generically a machine learning tool) which will consistently outperform competing approaches across all settings 67 . Therefore, given that we do not know F o r p e e r r e v i e w o n l y a priori which classifier will work best in this application, we will apply naïve Bayes classifiers for benchmarking, and then employ more advanced state of the art principled supervised learning algorithmic tools such as support vector machines, random forests, and ensembles (classifier combinations), to investigate which algorithm leads to more accurate results.
1. the original analysis dataset, 2. original data with additional duplicates of the positive outcome records (a method known as over-sampling 68 ), 3. original data, with a selection of the negative outcome records removed (undersampling 68 ), 4. original data with additional slightly modified duplicates of the positive outcome records, with a selection of the negative outcome records removed (Synthetic minority over-sampling; SMOTE 68, 69 ), 5. original data, using the outcome classification threshold to maximise the our primary metric -the Matthew's Correlation Coefficient (MCC) 70 -identified using goldensection search optimisation 71 .
In the validation partition, with all 100 iterations for the selected enrichment methods, we will identify the highest performing model as that with the highest mean MCC across iterations; in the event of a tie, the model with the highest iteration-minimum MCC will be selected.
Model testing will be conducted on the selected model ( Figure 1 ) in the derivation testing partitions. Model calibration will be assessed by comparing observed rate of incidence by predicted risk, for the full population and by exhaustive population subgroups, including asthma severity, prior number of asthma attacks, age and smoking status (particularly useful to assess possible contamination by asthma-COPD overlap syndrome (ACOS)). We will also check the calibration between the predicted risk and the attack incidence, stratified by the source of the asthma attack record (in primary care, A&E presentation, or inpatient admission). Performance in the testing datasets will be assessed using the MCC, and the additional metrics of sensitivity, specificity, positive predictive value and negative predictive value, and the F 1 measure 72 , along with information criteria such as the Bayesian Information Criterion (BIC) to obtain a trade-off between model complexity and accuracy. Confusion matrices (also known as contingency tables) will be made available as supplementary materials.
The derivation dataset will be re-used in its entirety to retrain the model based on the final classifier and hyperparameter selection. Model testing will then be conducted in the external dataset, which consists of data unseen in the model derivation, using this trained model. Distributions of predictors between the derivation and external datasets will be assessed (indirectly) to contextualise the generalisability findings. The aforementioned metrics will be reported. Finally, we will re-train the model using the hyperparameter specifications from the best performing model, with a modified version of the derivation dataset which incorporates data extracted from secondary care records (such as A&E presentations for asthma attack not captured in primary care records) in the determination of the risk factors. This allows us to evaluate the added value of secondary care data linkage in the prediction of impending asthma attacks, and will be determined by the same metrics used for the primary model evaluation.
All analyses will be conducted in R (though the RStudio interface), and details on the functions, the hyperparameter within each classifier, and the ranges assessed herein, are provided in Appendix B.
[ The subsequent research paper will be submitted for publication in a peer-reviewed journal and will be written in accordance with TRIPOD: transparent reporting of a multivariable prediction model for individual prognosis or diagnosis 73 and RECORD: reporting of studies conducted using observational routinely-collected health data 74 guidelines. Code scripts used for all components of the data cleaning, compiling, and analysis will be made available in the open source GitHub website at https://github.com/hollytibble.
[INSERT FIGURE 1 HERE]]
A lay summary of this protocol paper, and the subsequent research results paper, will be made available online (via an open source platform) in order to heighten the impact and accessibility of this work.
Data statement
Conclusions
Support Vector Machine
Implemented using the r function svm, from the package e1071 73 which builds upon the LIBSVM package 74 , using a radial basis kernel function. -GAMMA = Radial basis kernel function gamma parameter, corresponding to the kernel bandwidth (default 1/k): 2 (-5:10) -COST = Cost of constraints violation, i.e. samples penalised when crossing the boundary (default 1): 2 (-5:10) Ensemble: Bagging Bagging methods learn from multiple models which are staged in parallel.
Random Forests
Implemented using the r function randomForest, from the package of the same name 75 . -NTREE = Number of trees to grow (default 500): 500, 750, 1000 -MTRY = Number of variables randomly sampled as candidates at each split (default square root of the number of predictors; k): floor(0.5 * % ), floor(√ ), floor(2*% ) -in which floor represents the rounded-down integer value.
Ensemble: Boosting
Learning from multiple models which are staged sequentially, usually tree-based, constructed from different subsamples of the training dataset.
Extreme Gradient Boosting
Implemented using the r package xgboost 76 , with 10-fold cross validation, repeated 3 times. -NROUNDS = maximum number of iterations (default 100): 50,100 -MAXDEPTH = Maximum depth of each tree (default = 6): (1:5)^2 -ETA = step size of each boosting step (default = 0.3): 0.25, 0.5, 1
Ensemble: Stacking
Combining models from different classifiers, with an over-arching supervisor model which determines the best way to use all sources of information for prediction. The base set of weak learners will comprise all aforementioned model and hyperparameter combinations, and the meta-learner (random forest with 500 trees and mtry = floor(0.5 * % )) will use all weak learners with a validation set performance in the top 50%. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
